CL2024001303A1 - Compuestos y métodos dirigidos a la interleucina-34 - Google Patents
Compuestos y métodos dirigidos a la interleucina-34Info
- Publication number
- CL2024001303A1 CL2024001303A1 CL2024001303A CL2024001303A CL2024001303A1 CL 2024001303 A1 CL2024001303 A1 CL 2024001303A1 CL 2024001303 A CL2024001303 A CL 2024001303A CL 2024001303 A CL2024001303 A CL 2024001303A CL 2024001303 A1 CL2024001303 A1 CL 2024001303A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- methods targeting
- targeting interleukin
- methods
- antibodies
- Prior art date
Links
- 102100033499 Interleukin-34 Human genes 0.000 title abstract 2
- 101710181549 Interleukin-34 Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163273216P | 2021-10-29 | 2021-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024001303A1 true CL2024001303A1 (es) | 2024-08-30 |
Family
ID=84367272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001303A CL2024001303A1 (es) | 2021-10-29 | 2024-04-26 | Compuestos y métodos dirigidos a la interleucina-34 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11976114B2 (enExample) |
| EP (1) | EP4423127A1 (enExample) |
| JP (3) | JP7622019B2 (enExample) |
| KR (1) | KR20240099349A (enExample) |
| CN (1) | CN118475610A (enExample) |
| AR (1) | AR127484A1 (enExample) |
| AU (1) | AU2022376940A1 (enExample) |
| CA (1) | CA3236555A1 (enExample) |
| CL (1) | CL2024001303A1 (enExample) |
| CO (1) | CO2024005417A2 (enExample) |
| CR (1) | CR20240170A (enExample) |
| DO (1) | DOP2024000076A (enExample) |
| EC (1) | ECSP24032906A (enExample) |
| IL (1) | IL312380A (enExample) |
| MX (1) | MX2024005153A (enExample) |
| PE (1) | PE20241471A1 (enExample) |
| TW (1) | TW202336034A (enExample) |
| WO (1) | WO2023076995A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250064417A1 (en) * | 2022-02-03 | 2025-02-27 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3338796A1 (en) | 2008-07-21 | 2018-06-27 | Probiodrug AG | Diagnostic antibody assay |
| US8795664B2 (en) | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
| WO2012019061A2 (en) * | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| SG10201509330XA (en) | 2010-08-12 | 2015-12-30 | Lilly Co Eli | Anti-N3pGlu Amyloid Beta Peptide Antibodies And Uses Thereof |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| BR112014018961A8 (pt) | 2012-02-06 | 2017-07-11 | Genentech Inc | Anticorpo isolado, anticorpo biespecífico, fragmento, ácido nucleico isolado, vetor, célula hospedeira, método de produção de anticorpos, composição farmacêutica, uso do anticorpo, método de tratamento, método de inibição e artigo industrializado |
| MA40406A (fr) | 2014-07-28 | 2016-02-04 | Nogra Pharma Ltd | Procédés et compositions de diagnostic et de traitement des maladies inflammatoires chroniques de l'intestin |
| EP3233897B1 (en) * | 2014-12-19 | 2021-02-17 | Universite de Nantes | Anti il-34 antibodies |
| TWI703159B (zh) * | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| JP2018516933A (ja) | 2015-06-02 | 2018-06-28 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法 |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| WO2018031361A2 (en) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination therapy |
| JOP20190247A1 (ar) | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| CA3091810A1 (en) | 2018-03-02 | 2019-09-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of il-34 to treat retinal inflammation and neurodegeneration |
| EP3977135A1 (en) | 2019-05-31 | 2022-04-06 | Eli Lilly And Company | Compounds and methods targeting human tau |
| AR121898A1 (es) | 2020-04-30 | 2022-07-20 | Lilly Co Eli | Compuestos y métodos dirigidos a interleucina-34 |
-
2022
- 2022-10-27 MX MX2024005153A patent/MX2024005153A/es unknown
- 2022-10-27 PE PE2024000938A patent/PE20241471A1/es unknown
- 2022-10-27 EP EP22814582.7A patent/EP4423127A1/en active Pending
- 2022-10-27 AR ARP220102931A patent/AR127484A1/es unknown
- 2022-10-27 US US18/050,227 patent/US11976114B2/en active Active
- 2022-10-27 KR KR1020247017337A patent/KR20240099349A/ko active Pending
- 2022-10-27 TW TW111140796A patent/TW202336034A/zh unknown
- 2022-10-27 CA CA3236555A patent/CA3236555A1/en active Pending
- 2022-10-27 CR CR20240170A patent/CR20240170A/es unknown
- 2022-10-27 IL IL312380A patent/IL312380A/en unknown
- 2022-10-27 CN CN202280086946.7A patent/CN118475610A/zh active Pending
- 2022-10-27 WO PCT/US2022/078776 patent/WO2023076995A1/en not_active Ceased
- 2022-10-27 JP JP2022172479A patent/JP7622019B2/ja active Active
- 2022-10-27 AU AU2022376940A patent/AU2022376940A1/en active Pending
-
2024
- 2024-04-05 US US18/628,082 patent/US20240309082A1/en active Pending
- 2024-04-17 JP JP2024066552A patent/JP2024091777A/ja active Pending
- 2024-04-26 CL CL2024001303A patent/CL2024001303A1/es unknown
- 2024-04-26 DO DO2024000076A patent/DOP2024000076A/es unknown
- 2024-04-26 CO CONC2024/0005417A patent/CO2024005417A2/es unknown
- 2024-04-29 EC ECSENADI202432906A patent/ECSP24032906A/es unknown
-
2025
- 2025-01-15 JP JP2025005276A patent/JP2025063187A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022376940A1 (en) | 2024-05-02 |
| CA3236555A1 (en) | 2023-05-04 |
| JP2025063187A (ja) | 2025-04-15 |
| KR20240099349A (ko) | 2024-06-28 |
| US11976114B2 (en) | 2024-05-07 |
| EP4423127A1 (en) | 2024-09-04 |
| CO2024005417A2 (es) | 2024-05-30 |
| TW202336034A (zh) | 2023-09-16 |
| AR127484A1 (es) | 2024-01-31 |
| DOP2024000076A (es) | 2024-06-16 |
| US20230279094A1 (en) | 2023-09-07 |
| IL312380A (en) | 2024-06-01 |
| JP2023067832A (ja) | 2023-05-16 |
| CR20240170A (es) | 2024-05-24 |
| US20240309082A1 (en) | 2024-09-19 |
| MX2024005153A (es) | 2024-05-13 |
| CN118475610A (zh) | 2024-08-09 |
| PE20241471A1 (es) | 2024-07-17 |
| JP2024091777A (ja) | 2024-07-05 |
| WO2023076995A1 (en) | 2023-05-04 |
| JP7622019B2 (ja) | 2025-01-27 |
| ECSP24032906A (es) | 2024-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22084245A (es) | Compuestos y métodos dirigidos a interleucina-34 | |
| CO2020014575A2 (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos | |
| CO2022013274A2 (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
| ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2021009246A (es) | Inmunomoduladores, composiciones y metodos de los mismos. | |
| UY38476A (es) | Inhibidores de arg1 y/o arg2 | |
| CO2019007830A2 (es) | Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas | |
| UY37378A (es) | Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus | |
| MX376212B (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo. | |
| DOP2021000229A (es) | Materiales y métodos para modular la inmunidad mediada por cédula t | |
| CL2023002966A1 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
| CR20220228A (es) | Anticuerpos trem2 y usos de estos | |
| MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
| CL2020000070A1 (es) | Agentes, usos y métodos para el tratamiento. | |
| CL2024001303A1 (es) | Compuestos y métodos dirigidos a la interleucina-34 | |
| BR112022000297A2 (pt) | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos | |
| CO2021009309A2 (es) | Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo | |
| BR112022012153A2 (pt) | Processo para preparar um composto e composto | |
| MX2021015501A (es) | Anticuerpos y metodos de uso. | |
| CO6270365A2 (es) | Derivado heterociclico con una sal farmaceuticamente aceptable o solvato del mismo y composicion que lo comprende | |
| MX2019013524A (es) | Composiciones para tratar enfermedades neurodegenerativas. | |
| UY39699A (es) | Anticuerpos anti-tau y usos de estos | |
| MX2021006865A (es) | Anticuerpos anti-alfa-sinucleina y usos de estos. |